Gynecologic investigation最新文献

The systemic absorption and the plasma concentrations of chloroquinaldol have been determined after local application of one vaginal tablet of Sterosan. A peak plasma concentration of 33 ng/ml was determined 12 h after application. A mean absorption of 6.0% of the applied dose was estimated.

In 101 hypertensive gravidae the selective beta-blocking agent metoprolol alone or in combination with hydralazine has been used. The effects of the mother and fetus have been compared with those of 97 hypertensive gravidae treated with hydralazine. In both groups a small dose of a thiazide was added. Perinatal mortality was lower in the metoprolol group (2.0%) than in the hydralazine group (8.0%). The rate of fetal growth retardations also was lower when using metoprolol (11.7 and 16.3% respectively). No abnormal effects of the beta-blocker was noticed on the fetus.

107 parous women wearing Szontágh-type IUDs were treated with either etamsylate or placebo tablets by a double-blind technique with random allocation. The length of the cycles, the duration of menstrual bleeding and the amount of bleeding were analyzed. Etamsylate treatment favourably influenced menstrual bleeding in IUD users. In the etamsylate group, the number of "bleeding days' and the amount of menstrual flow were significantly less than in the placebo group.

As important discrepancies in blood concentrations of LH-RH remain, the basic problem of the specificity of the radioimmunoassay was reinvestigated using an antiserum raised against a new conjugate (33). Cross-reactions with related and unrelated peptides were studied in both charcoal-dextran and second antibody methods of separation. The possible relation between the nature of the conjugate and the specificity is discussed.

To acertain whether human placental lactogen (HPL) functions as a luteotropin during pregnancy in humans, studies were performed to determine if receptors for HPL are present in cells of the human corpus luteum of late pregnancy. Preparations of 125I-HPL which demonstrated specific binding to late pregnant rabbit mammary gland cell homogenates showed specific binding of less than 2.5% to homogenates of human corpora lutea of late pregnancy. These studies indicate that HPL is not luteotropic at this stage of pregnancy in humans. The action of HPL upon the corpus luteum appears to vary considerably according to species.

The lecithin content of 157 amniotic fluid samples taken from 60 patients who had been treated with Fenoterol over a long period of time (longer than 30 mg/daily per os for 14 days; intravenous infusion for longer than 7 days) was calculated thin-layer chromatographically according to Kynast and Saling. These lecithin levels were statistically compared with the levels in a control (Wilcoxon test). It emerged that the lecithin levels in the long-term beta-mimetic therapy group were significantly lower, i.e., from 33/0 to 39/6 (33/0-34/6, p less than 0.05; 35/0-39/6, p less than 0.01). The answer to the question how often levels occur in the long-term group which are below the as critical described level of 3 mg Lec/100 ml amniotic fluid appears to be clinically important. It is shown that values below the critical level from 33/0 to 39/6 are much more frequent in the long-term beta-mimetics therapy group than in the control group. There is no known explanation for this. It was concluded that the application of beta-mimetics in cases of long-term tocolysis should only be discontinued when the lecithin content of the amniotic fluid lies above the critical limit of 3 mg Lec/100 ml.

Comparison of standard curves with different concentrations of human plasma in the medium of incubation is presented. It appears that Bo varies with the dilution although the ratio B/Bo is independent of the dilution. This last observation was used to research 'endogenous' LH-RH in four menstrual cycles, in postmenopausal women and in men. The validity of the dosage is discussed in a more general way in the light of the results published in the literature.